5508-58-7|Andrographolide，≥98%|Medlife|Medlife为MCE，Selleck，麦克林，阿拉丁试剂，罗恩试剂，Sigma，安耐吉试剂，泰坦等同类产品品牌，上海现货，高性价比小分子化合物

您当前的位置：

Andrographolide

NF-κB信号抑制剂，Andrographolide 是一种 NF-κB 抑制剂，通过共价修饰内皮细胞中 p50 的半胱氨酸残基而抑制 NF-κB 活化，而不影响 IκBα 降解或 p50/p65 核易位。

目录号: PC11621 纯度: ≥98%

CAS No. :5508-58-7

商品编号	规格	价格	会员价
PC11621-100mg	100mg	¥392.00	请登录
PC11621-500mg	500mg	¥1176.00	请登录
PC11621-10mM (in 1mL DMSO)	10mM (in 1mL DMSO)	¥490.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称

Andrographolide

中文别名

穿心莲内酯;心莲乙素;雄茸内酯;穿心莲;穿心连内酯;穿心连内脂;穿心莲内酯, 来源于穿心莲;白柳皮提取物;吡罗西康;穿琥宁;穿心莲内脂;穿心莲内酯 USP标准品;穿心莲内酯标准品;穿心莲内酯(P);穿心莲内酯(SH);穿心莲内酯（标准品）;穿心莲内酯对照品;穿心莲内酯对照品标准品;穿心莲提取物;头孢替坦二钠;穿心莲乙素;穿心莲乙素植物提取物,标准品,对照品;穿心莲总内酯;对甲基氯化苄;分析对照品;柴胡皂苷B;橙皮素;穿心莲素;滇乌头碱;碘化木兰花碱;雄茸内脂;印乌头碱;兽用穿心莲提取物

英文名称

Andrographolide

英文别名

Andrographolide;ANDRO;ANDROGRAPHIS;3A,14,15,18-TETRAHYDROXY-5B,9B,H,10A-LAMBDA-8,20-DIENE;2(3H)-FURANONE,3-[2-[(1R,4AS,5R,6R,8AS)-DECAHYDRO-6-HYDROXY-5-(HYDROXYMETHYL)-5,8A-DIMETHYL-2-METHYLENE-1-NAPHTHALENYL]ETHYLIDENE]DIHYDRO-4-HYDROXY-, (3E,4S)-;2(3h)-furanone,3-(2-(decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-met;hylene-1-naphthalenyl)ethylidene)dihydro-4-hydroxy-,(1r-(1-alpha(e(s*)),4a-be;(S,E)-4-Hydroxy-3-(2-((1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethylidene)dihydrofuran-2(3H)-one;ANDROGRAPHOLIDE(P);ANDROGRAPHOLIDE(SH) PrintBack;alpha-Chloro-p-xylene;Andrographalide;Andrographolid;Rhizoma Sparganii;(3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-2(3H)-furanone;ent-(3β,12E,14R)-3,14,19-Trihydroxy-8(17),12-labdadien-16,15-olide;andrographolidume;[ "" ];410105JHGR;Andropanolide;3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one;(3E,4S)-4-hydroxy-3

Cas No.

5508-58-7

分子式

C₂₀H₃₀O₅

分子量

350.45

包装储存

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

生物活性

Andrographolide is a NF-κB inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on p50 in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide has antiviral effects.

性状

Solid

IC50 & Target[1][2]

p50

体外研究(In Vitro)

Andrographolide (AP) concentration-dependently suppresses receptor activator of nuclear factor kappa B ligand (RANKL)-mediated osteoclast differentiation and bone resorption 体外研究 and reduces the expression of osteoclast-specific markers. Andrographolide attenuates inflammation by inhibition of TNFα-induced NF-κB activation through covalent modification of reduced Cys of p50, without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide also inhibits the ERK/MAPK signalling pathway without affecting p38 or JNK signalling. Andrographolide inhibits osteoclast differentiation of RAW 264.7 cells in a concentration-dependent manner. Andrographolide suppresses osteoclast formation in a concentration-dependent manner without any obvious cytotoxic effects, in both BMMs and RAW 264.7 cells. Andrographolide treatment substantially reduces the area of bone resorption. Only approximately 30% of the bone resorption observed in the control group is achieved after treatment with 2.5?μM Andrographolide. Osteoclastic bone resorption is almost completely inhibited after treatment with 10?μM Andrographolide.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Treatment with Andrographolide (5 or 30?mg/kg) reduces the extent of bone loss induced by LPS. Moreover, Andrographolide slightly increases the BMD and cortex thickness compared to LPS treatment. Histological examination confirms the protective effects of Andrographolide on LPS-induced bone loss. LPS injection leads to inflammatory bone erosion and increased numbers of TRAP-positive osteoclasts.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature or refrigerated transportation.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

ClinicalTrial

结构分类

来源

参考文献

[1]. Zhai ZJ, et al. Andrographolide suppresses RANKL-induced osteoclastogenesis 体外研究 and prevents inflammatory bone loss in vivo. Br J Pharmacol. 2014 Feb;171(3):663-75. [Information]

[2]. Gupta S, et al. Broad-spectrum antiviral properties of andrographolide. Arch Virol. 2017 Mar;162(3):611-623. [Information]

溶解度数据

体外研究:

DMSO : 100 mg/mL (285.35 mM; Need ultrasonic)

H₂O : 0.1 mg/mL (0.29 mM; Need ultrasonic)

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.8535 mL	14.2674 mL	28.5347 mL
5 mM	0.5707 mL	2.8535 mL	5.7069 mL
10 mM	0.2853 mL	1.4267 mL	2.8535 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (7.13 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.13 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH?O 中，得到澄清透明的生理盐水溶液
2.

建议依照次序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (7.13 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.13 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

建议依照次序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.13 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.13 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation